LSP in €21.7m series B round for Merus

Merus' seed investor Aglaia Oncology Fund also participated in this financing. Alongside with this financing, the Company also entered into an option agreement with the Novartis Option Fund for an exclusive license to one of Merus' oncology programs. The agreement includes upfront and potential milestones payments totaling over $200m plus royalties.

The financing will allow Merus to further advance its product pipeline in oncology, inflammation and infectious disease.

Situated in Utrecht the company uses its proprietary technology platforms to produce new highly potent human antibody-based drugs whether as full-length bispecific antibodies or as mixtures of therapeutic human monoclonal antibodies produced by a single cell (Oligoclonics™).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Benelux
• Netherlands
• Life Science Partners